MA29677B1 - Medicament prophylactique ou therapeutique contre la depression ou la nevrose d'angoisse - Google Patents

Medicament prophylactique ou therapeutique contre la depression ou la nevrose d'angoisse

Info

Publication number
MA29677B1
MA29677B1 MA30311A MA30311A MA29677B1 MA 29677 B1 MA29677 B1 MA 29677B1 MA 30311 A MA30311 A MA 30311A MA 30311 A MA30311 A MA 30311A MA 29677 B1 MA29677 B1 MA 29677B1
Authority
MA
Morocco
Prior art keywords
prophylactic
depression
therapeutic drug
nevrose
angoisse
Prior art date
Application number
MA30311A
Other languages
English (en)
Inventor
Keisuke Hirai
Masaomi Miyamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37073564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29677(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA29677B1 publication Critical patent/MA29677B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention divulgue un médicament prophylactique ou thérapeutique contre la dépression ou la névrose d'angoisse, contenant le (S)-N-[2-(l,6,7,8-tétrahydro-2H-indéno[5,4-b]furane-8-yl)éthyl]propionamide.
MA30311A 2005-04-04 2007-10-25 Medicament prophylactique ou therapeutique contre la depression ou la nevrose d'angoisse MA29677B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005107674 2005-04-04

Publications (1)

Publication Number Publication Date
MA29677B1 true MA29677B1 (fr) 2008-08-01

Family

ID=37073564

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30311A MA29677B1 (fr) 2005-04-04 2007-10-25 Medicament prophylactique ou therapeutique contre la depression ou la nevrose d'angoisse

Country Status (23)

Country Link
US (1) US20090042861A1 (fr)
EP (1) EP1867641A4 (fr)
JP (1) JP5259181B2 (fr)
KR (1) KR20070118103A (fr)
CN (1) CN101189219A (fr)
AR (1) AR054435A1 (fr)
AU (1) AU2006231752B2 (fr)
BR (1) BRPI0607684A2 (fr)
CA (1) CA2602267A1 (fr)
CL (1) CL2009000980A1 (fr)
CR (1) CR9385A (fr)
GE (1) GEP20105001B (fr)
IL (1) IL186049A0 (fr)
MA (1) MA29677B1 (fr)
MY (1) MY142214A (fr)
NO (1) NO20075599L (fr)
NZ (1) NZ561677A (fr)
PE (1) PE20061355A1 (fr)
RU (1) RU2413510C2 (fr)
TW (1) TWI391132B (fr)
UA (1) UA89397C2 (fr)
WO (1) WO2006107019A1 (fr)
ZA (1) ZA200708445B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2248808B1 (fr) * 2008-01-31 2014-07-16 Takeda Pharmaceutical Company Limited Agent prophylactique ou thérapeutique pour le trouble du déficit de l'attention avec hyperactivité
US8426461B2 (en) 2011-01-17 2013-04-23 Takeda Pharmaceutical Company Limited Orally dispersible tablet
AR084865A1 (es) * 2011-01-17 2013-07-10 Takeda Pharmaceutical Preparacion de desintegracion rapida, comprimido dispersable por via oral
WO2013054582A1 (fr) * 2011-10-14 2013-04-18 Takeda Pharmaceutical Company Limited Comprimé dispersible par voie orale
CN102718675B (zh) * 2012-06-07 2015-03-25 上海右手医药科技开发有限公司 阿戈美拉汀甲磺酸复合物及其制备方法
RU2571546C1 (ru) * 2014-07-14 2015-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ дифференцированной диагностики и терапии синдрома ночной еды
BR112019019242A2 (pt) 2017-03-30 2020-04-14 Jose Eduardo Penello Temporao composição multivitamínica para aprimoramento da fluência verbal, dimimuição dos sintomas da ansiedade de performance e seu método e preparação
CN108451917A (zh) * 2018-03-22 2018-08-28 仁和堂药业有限公司 高稳定性米安色林制剂的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
ES2170798T3 (es) * 1994-06-10 2002-08-16 Smithkline Beecham Plc Benzopiranos y su uso como agentes terapeuticos.
US5780470A (en) * 1995-06-02 1998-07-14 Bristol-Myers Squibb Company Melatonergic indanyl piperazines
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
DE69713294T3 (de) * 1996-03-08 2009-01-15 Takeda Pharmaceutical Co. Ltd. Tricyclische Verbindungen mit Bindungsaffinität für Melatoninrezeptoren, deren Herstellung und Verwendung
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
AU4060599A (en) * 1998-06-09 1999-12-30 Takeda Chemical Industries Ltd. Pharmaceutical composition for treating or preventing sleep disorders
AU2001266342B2 (en) * 2000-06-27 2005-01-27 Taisho Pharmaceutical Co., Ltd. Remedial agent for anxiety neurosis or depression and piperazine derivative
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
WO2003022283A1 (fr) * 2001-09-13 2003-03-20 Schering Corporation Combinaison d'un antagoniste du recepteur d'adenosine a2a et d'un antidepresseur ou d'un anxiolytique
US20070088079A1 (en) * 2005-09-20 2007-04-19 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for sleep disorder

Also Published As

Publication number Publication date
NZ561677A (en) 2011-02-25
EP1867641A4 (fr) 2010-01-13
WO2006107019A1 (fr) 2006-10-12
GEP20105001B (en) 2010-06-10
AU2006231752A1 (en) 2006-10-12
ZA200708445B (en) 2009-03-25
TWI391132B (zh) 2013-04-01
JP5259181B2 (ja) 2013-08-07
UA89397C2 (ru) 2010-01-25
AR054435A1 (es) 2007-06-27
MY142214A (en) 2010-11-15
KR20070118103A (ko) 2007-12-13
RU2007140986A (ru) 2009-05-20
CA2602267A1 (fr) 2006-10-12
CL2009000980A1 (es) 2009-08-14
US20090042861A1 (en) 2009-02-12
IL186049A0 (en) 2008-02-09
PE20061355A1 (es) 2007-01-15
NO20075599L (no) 2007-12-19
TW200719885A (en) 2007-06-01
CR9385A (es) 2007-12-07
RU2413510C2 (ru) 2011-03-10
EP1867641A1 (fr) 2007-12-19
AU2006231752B2 (en) 2012-03-01
CN101189219A (zh) 2008-05-28
JPWO2006107019A1 (ja) 2008-09-25
BRPI0607684A2 (pt) 2009-09-22

Similar Documents

Publication Publication Date Title
MA29677B1 (fr) Medicament prophylactique ou therapeutique contre la depression ou la nevrose d'angoisse
EA200400481A1 (ru) Применение флибансерина для лечения половых расстройств
WO2007010034A3 (fr) Copolymere ampholyte, sa production et son utilisation
MXPA06007171A (es) Derivados de ciclohexano espirociclicos con afinidad para el receptor orl1.
MY148459A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
RS99804A (en) Novel compounds and their use
FR2909867B3 (fr) Capsule remplie d'un medicament, en particulier d'un medicament inhalable.
DK1511489T3 (da) Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A
MXPA04002510A (es) Combinacion de opioides selectos con antagonistas de muscarina para tratamiento de incontinencia urinaria.
ITMO20040351A1 (it) ''confezione per prodotti framaceutici,medicinali o simili,particolarmente fitofarmaci o fitosanitari''.
EA200501697A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
MY140538A (en) Substituted n-acyl-2-aminothiazoles
PT1713438E (pt) Sabonete medicinal
HRP20040186B1 (en) Use of lhrh-antagonists for the improvement of t-cell mediated immunity
RS50523B (sr) Farmaceutska kompozicija koja sadrži cink-hijaluronat kompleks za lečenje multiple skleroze
FR2885812B1 (fr) Medicament a base de laminarine ou d'oligolaminarines pour le traitement de la septicemie et du choc septique
EP1867642A4 (fr) Agent pour la prevention ou le traitement d'un trouble nocturne du comportement associe a la demence
GEP20084546B (en) Novel association consisting of an anti-atherothrombotic agent and of platelet antiaggregating agent
UY27376A1 (es) Formulación de medicamento que contiene un antagonista de ltb4
ITMI20041822A1 (it) "agente terapeutico utile per il trattamento di neoplasie plasmacellulari"
MX2007012219A (es) Medida de prevencion o remedio para neurosis paro depresion o ansiedad.
ITVI20040153A1 (it) Dispositivo di gioco, particolarmente per la ricerca dell'equilibrio statico di un corpo
SI1532124T1 (sl) Uporaba nitrilnih derivatov kot zdravila
RU2004113222A (ru) Применение препарата "реамберин-1,5% для инфузий" в качестве средства снижения вязкости крови (плазмы)
BRPI0402854A (pt) tratamento e estudo do melanoma com a utilização dos compostos 1,3,4-tiadiazois mesoiÈnicos